Pending a successful acquisition, Novartis will obtain pelabresib for myelofibro...
The potentially disastrous consequences of antimicrobial resistance (AMR) were h...
The Belgian women’s health company is exploring multiple asset and licensing sel...
The China NMPA has granted clearance for the investigational new drug (IND) appl...
J&J’s nipocalimab met primary endpoints in Phase III and II trials for myastheni...
“This is very significant. It’s massive.” Read about the woman suing her employe...
Novartis said late Monday it has agreed to buy German biotech MorphoSys and its ...
The bankruptcy of primary care provider Cano Health, a company once valued at $4...
A Democrat was willing to sign on to legislation that would weaken Medicare's po...
The big takeaway from CMS’ newest proposals for Medicare Advantage: the Biden ad...
Diabetes treatments have improperly listed patents that should be removed, a new...
Monday’s announcement that the parent company of Novo Nordisk plans to buy Catal...
After a months-long fight with Texas Medicaid over coverage of a gene therapy, A...
Regeneron is interested in obesity treatments that combat muscle loss — potentia...
The investment arm of Novo Nordisk’s parent foundation is buying Catalent, a con...
An investment group tied to Novo Nordisk is buying drug manufacturer Catalent fo...
